Stoke Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
128
- Stock Symbol
-
STOK
- Share Price
-
$7.40
- (As of Wednesday Closing)
Stoke Therapeutics General Information
Description
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Contact Information
Website
www.stoketherapeutics.comCorporate Office
- 45 Wiggins Avenue
- Bedford, MA 01730
- United States
Corporate Office
- 45 Wiggins Avenue
- Bedford, MA 01730
- United States
Stoke Therapeutics Stock Performance
As of 26-Mar-2025, Stoke Therapeutics’s stock price is $7.40. Its current market cap is $400M with 54.1M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.40 | $7.74 | $7.18 - $17.58 | $400M | 54.1M | 828K | -$1.65 |
Stoke Therapeutics Financials Summary
As of 31-Dec-2024, Stoke Therapeutics has a trailing 12-month revenue of $36.6M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 347,324 | 347,324 | 22,659 | 114,604 |
| Revenue | 36,555 | 36,555 | 8,780 | 12,405 |
| EBITDA | (99,419) | (99,419) | (112,107) | (102,643) |
| Net Income | (88,981) | (88,981) | (104,699) | (101,067) |
| Total Assets | 271,555 | 271,555 | 228,342 | 256,067 |
| Total Debt | 2,322 | 2,322 | 2,062 | 2,359 |
Stoke Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Stoke Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Stoke Therapeutics Comparisons
Industry
Financing
Details
Stoke Therapeutics Competitors (102)
One of Stoke Therapeutics’s 102 competitors is Abeona Therapeutics, a Corporation company based in Cleveland, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Stoke Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Stoke Therapeutics Patents
Stoke Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250066781-A1 | Methods for treating conditions and diseases | Pending | 24-Jul-2023 | ||
| AU-2023314419-A1 | Compounds for treatment of conditions and diseases | Pending | 29-Jul-2022 | ||
| EP-4429714-A2 | Opa1 antisense oligomers for treatment of conditions and diseases | Pending | 09-Nov-2021 | ||
| US-20250059535-A1 | Opa1 antisense oligomers for treatment of conditions and diseases | Pending | 09-Nov-2021 | ||
| EP-4359538-A2 | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | Pending | 21-Jun-2021 | C12N15/113 |
Stoke Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Stoke Therapeutics ESG
Risk Overview
Risk Rating
Updated May, 24, 2023
25.2 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Stoke Therapeutics FAQs
-
When was Stoke Therapeutics founded?
Stoke Therapeutics was founded in 2014.
-
Where is Stoke Therapeutics headquartered?
Stoke Therapeutics is headquartered in Bedford, MA.
-
What is the size of Stoke Therapeutics?
Stoke Therapeutics has 128 total employees.
-
What industry is Stoke Therapeutics in?
Stoke Therapeutics’s primary industry is Drug Discovery.
-
Is Stoke Therapeutics a private or public company?
Stoke Therapeutics is a Public company.
-
What is Stoke Therapeutics’s stock symbol?
The ticker symbol for Stoke Therapeutics is STOK.
-
What is the current stock price of Stoke Therapeutics?
As of 26-Mar-2025 the stock price of Stoke Therapeutics is $7.40.
-
What is the current market cap of Stoke Therapeutics?
The current market capitalization of Stoke Therapeutics is $400M.
-
What is Stoke Therapeutics’s current revenue?
The trailing twelve month revenue for Stoke Therapeutics is $36.6M.
-
Who are Stoke Therapeutics’s competitors?
Abeona Therapeutics, Renova Therapeutics, Adaptimmune Therapeutics, Dicerna Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 102 competitors of Stoke Therapeutics.
-
What is Stoke Therapeutics’s annual earnings per share (EPS)?
Stoke Therapeutics’s EPS for 12 months was -$1.65.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
